4.7 Article

Evolution of anosognosia in alzheimer disease and its relationship to amyloid

Journal

ANNALS OF NEUROLOGY
Volume 87, Issue 2, Pages 267-280

Publisher

WILEY
DOI: 10.1002/ana.25649

Keywords

-

Funding

  1. ADNI (NIH) [U01 AG024904]
  2. ADNI (Department of Defense) [W81XWH-12-2-0012]
  3. NIH National Institute on Aging
  4. NIH National Institute of Biomedical Imaging and Bioengineering
  5. AbbVie
  6. Alzheimer's Association
  7. Alzheimer's Drug Discovery Foundation
  8. Araclon Biotech
  9. BioClinica
  10. Biogen
  11. Bristol-Myers Squibb Company
  12. CereSpir
  13. Cogstate
  14. Eisai
  15. Elan Pharmaceuticals
  16. Eli Lilly and Company
  17. EuroImmun
  18. F. Hoffmann-La Roche
  19. Genentech
  20. Fujirebio
  21. GE Healthcare
  22. IXICO
  23. Janssen Alzheimer Immunotherapy Research Development
  24. Johnson & Johnson Pharmaceutical Research Development
  25. Lumosity
  26. Lundbeck
  27. Merck Co
  28. Meso Scale Diagnostics
  29. NeuroRx Research
  30. Neurotrack Technologies
  31. Novartis Pharmaceuticals Corporation
  32. Pfizer
  33. Piramal Imaging
  34. Servier
  35. Takeda Pharmaceutical Company
  36. Transition Therapeutics
  37. Canadian Institutes of Health Research

Ask authors/readers for more resources

Objective Unawareness, or anosognosia, of memory deficits is a challenging manifestation of Alzheimer disease (AD) that adversely affects a patient's safety and decision-making. However, there is a lack of consensus regarding the presence, as well as the evolution, of altered awareness of memory function across the preclinical and prodromal stages of AD. Here, we aimed to characterize change in awareness of memory abilities and its relationship to beta-amyloid (A beta) burden in a large cohort (N = 1,070) of individuals across the disease spectrum. Methods Memory awareness was longitudinally assessed (average number of visits = 4.3) and operationalized using the discrepancy between mean participant and partner report on the Everyday Cognition scale (memory domain). A beta deposition was measured at baseline using [18F]florbetapir positron emission tomographic imaging. Results A beta predicted longitudinal changes in memory awareness, such that awareness decreased faster in participants with increased A beta burden. A beta and clinical group interacted to predict change in memory awareness, demonstrating the strongest effect in dementia participants, but could also be found in the cognitively normal (CN) participants. In a subset of CN participants who progressed to mild cognitive impairment (MCI), heightened memory awareness was observed up to 1.6 years before MCI diagnosis, with memory awareness declining until the time of progression to MCI (-0.08 discrepant-points/yr). In a subset of MCI participants who progressed to dementia, awareness was low initially and continued to decline (-0.23 discrepant-points/yr), reaching anosognosia 3.2 years before dementia onset. Interpretation A beta burden is associated with a progressive decrease in self-awareness of memory deficits, reaching anosognosia approximately 3 years before dementia diagnosis. ANN NEUROL 2019

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available